Being hospitalized for heart failure is hard enough, but an added burden that happens to 1 in 5 patients within 30 days of being discharged from the hospital is having to be readmitted.
In essence, this creates a revolving door situation for all involved.
But the exciting thing about InnaMed is that it has potentially found a solution to this all too common problem.
InnaMed’s proprietary smart, at-home blood testing device called TeleLab allows for remote monitoring. And considering that 70% of clinical decisions require a blood test, their product could potentially revolutionize the at-home telemedical sector.
The process is quite user-friendly. Simply place their cartridge on your upper arm, push the button for a painless blood draw and then insert the cartridge into the TeleLab reader.
The Future of InnaMed
InnaMed plans to begin with heart failure patients, with plans to cross over into multiple medical applications.
What Interested Investors Need to Know
Three things that investors should take note of:
- They’re beginning with the cardiac diagnostics market which is $3B+, with intentions to expand to the general lab testing market which is $50B+.
- They’ve already secured letters of intent from eight leading hospital systems.
- Their executive team brings multiple eight and nine-figure previous exit ventures to the table.